Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Adjuvant Triptorelin vs No Further Treatment in Locally Advanced Prostate Cancer
NCT00003026Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 1997
- Primary completion
- Sep 2001
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of triptorelin in prostate cancer (PCa) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Overall Survival at 5 years and Clinical Disease Free Survival at 5 years. Started Apr 1997; status: completed.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00003026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003026.